Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-12-31Clinical Trial Update: Overactive Bladder Education [NA]
Hartford Hospital-sponsored clinical trial evaluating education for overactive bladder was terminated.
-
CLINICAL_TRIALS trial_result · 2015-12-18Clinical Trial Update: Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence [Phase 3]
Phase 3 long-term follow-up study of Botulinum Toxin Type A for idiopathic overactive bladder with urinary incontinence completed; results p…
-
CLINICAL_TRIALS research · 2015-12-18Clinical Trial Update: Gene Expression in the Overactive Bladder in Children
An update on a study examining gene expression in pediatric overactive bladder, with the current status of the trial not disclosed.
-
CLINICAL_TRIALS trial_result · 2015-12-17Clinical Trial Update: A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007) [Phase 2]
Phase 2 placebo-controlled trial of MK0634 for overactive bladder/urinary incontinence has completed.
-
FDA approval · 2015-12-10FDA Approved: FESOTERODINE FUMARATE — Original Application (Ascend Laboratories, LLC)
The FDA approved the original application for fesoterodine fumarate (generic) manufactured by Ascend Laboratories, LLC, as a generic version…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-12-07Clinical Trial Update: Bacterial Genomic Sequencing in Overactive Bladder [Phase 2]
Phase 2 clinical trial sponsored by Loyola University has completed. The study investigates bacterial genomic sequencing in Overactive Bladd…
-
CLINICAL_TRIALS safety_alert · 2015-12-04Clinical Trial Update: Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists
This completed clinical trial update discusses cardiovascular morbidity observed during treatment of overactive bladder with beta-3 adrenerg…
-
FDA approval · 2015-11-23FDA Approved: OXYBUTYNIN CHLORIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal's original application for a generic oxybutynin chloride product.
-
FDA approval · 2015-11-04FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA supplemental approval for oxybutynin chloride submitted by Chartwell RX, LLC for an existing generic product.
-
FDA approval · 2015-11-02FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for MYRBETRIQ (mirabegron) submitted by Astellas Pharma US, Inc.
-
CLINICAL_TRIALS research · 2015-10-22Clinical Trial Update: Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation [EARLY_Phase 1]
Early-phase clinical trial update on using back tibial nerve electrostimulation to treat neurogenic overactive bladder in Parkinson disease.
-
CLINICAL_TRIALS trial_result · 2015-10-07Clinical Trial Update: Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease
Completed trial results from a use-survey of Betanis tablets in patients with overactive bladder and cardiovascular disease.
-
CLINICAL_TRIALS trial_result · 2015-10-05Clinical Trial Update: Drug Use-Results Survey of Betanis Tablets in Japan
This completed trial update reports results of a drug-use survey of Betanis tablets for overactive bladder in Japan.
-
FDA approval · 2015-09-25FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for tolterodine tartrate submitted by Teva Pharmaceuticals USA, Inc. for a generic product.
-
CLINICAL_TRIALS trial_result · 2015-09-04Clinical Trial Update: Toviaz Post Marketing Surveillance Study
Post-marketing surveillance study of fesoterodine (Toviaz) for overactive bladder completed; results were posted on 2015-09-04.
-
CLINICAL_TRIALS withdrawal · 2015-09-02Clinical Trial Update: A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
A clinical trial assessing changes in an overactive bladder medication sponsored by Astellas Pharma Inc has been withdrawn.
-
FDA approval · 2015-08-31FDA Approved: TOLTERODINE TARTRATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods Pharmaceuticals Limited's tolterodine tartrate as an original ANDA, enabling a generic tolterodine tartrate product fo…
-
FDA approval · 2015-08-11FDA Approved: TOLTERODINE TARTRATE — Original Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's original application for tolterodine tartrate (tolterodine), a generic treatment for overacti…
-
FDA approval · 2015-08-10FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for MYRBETRIQ (mirabegron) submitted by Astellas Pharma US, Inc.
-
CLINICAL_TRIALS trial_result · 2015-07-21Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder [Phase 2]
This Phase 2 study evaluated mirabegron and solifenacin (alone and in combination) for overactive bladder, assessing efficacy, safety and to…
-
FDA approval · 2015-07-10FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental application for OXYTROL (oxybutynin). The approval updates the product labeling under NDA 021351.
-
CLINICAL_TRIALS research · 2015-07-07Clinical Trial Update: Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients [Phase 4]
A Phase 4 clinical trial compares 3-month versus 6-month solifenacin treatment for female overactive bladder, with current status listed as …
-
CLINICAL_TRIALS withdrawal · 2015-06-26Clinical Trial Update: Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach. [Phase 2]
A Phase 2 clinical trial evaluating botulinum toxin type A injections for detrusor hyperreflexia in spinal cord injury was withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-06-22Clinical Trial Update: Brain Areas Involved in Bladder Filling and Contraction [NA]
A Maastricht University Medical Center trial studies brain regions involved in bladder filling and contraction in individuals with overactiv…
-
CLINICAL_TRIALS trial_result · 2015-06-03Clinical Trial Update: Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder [Phase 2]
A Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of Dexmecamylamine (TC-5214) for overactive bladder has completed…